Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002239 · ClinicalTrials.gov registry record · Phase 2
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
A Phase 2 study of HIV Infections, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 20
- Study locations
NCT00002239 is a Phase 2 study of HIV Infections that has completed, run by Hoffmann-La Roche. The registered enrollment target is 68 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00002239, a Phase 2 study of HIV Infections, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs. The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV). Three different doses of T-20 are tested.
Conditions Studied
Interventions
- DRUG Ritonavir
- DRUG Efavirenz
- DRUG Abacavir sulfate
- DRUG Amprenavir
- DRUG Enfuvirtide
Study Locations (20)
California
- Pacific Oaks Research - Beverly Hills
- UCLA Care Ctr - Los Angeles
- ViRx Inc - Palm Springs
- Donald Northfelt - Palm Springs
- UCSD - San Diego
- ViRx Inc - San Francisco
- Quest Clinical Research - San Francisco
Pennsylvania
- Pennsylvania Oncology and Hematology Associates - Philadelphia
- Philadelphia FIGHT - Philadelphia
- Univ of Pittsburgh - Pittsburgh
Florida
- IDC Research Initiative - Altamonte Springs
- Gary Richmond MD - Fort Lauderdale
District of Columbia
- Dupont Circle Physicians Group - Washington D.C.
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
Maryland
- Johns Hopkins Hosp - Baltimore
Missouri
- Washington Univ School of Medicine - St Louis
New York
- New York Univ Med Ctr - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 1999-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002239
The ClinicalTrials.gov registry entry for NCT00002239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (85% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Ritonavir is the first listed.
NCT00002239 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Pennsylvania, Florida.
Frequently Asked Questions
What is clinical trial NCT00002239 about?
NCT00002239 is a clinical study titled "A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults". The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs. The other anti-HIV drugs used are abacavir (ABC), amprenavir (APV), ritonavir (RTV), and efavirenz (EFV). Three different doses of T-20 are tested.
What is the current status of trial NCT00002239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 1999-05.
What conditions does trial NCT00002239 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002239?
The interventions under investigation include: Ritonavir (DRUG), Efavirenz (DRUG), Abacavir sulfate (DRUG), Amprenavir (DRUG), Enfuvirtide (DRUG).
Who is sponsoring clinical trial NCT00002239?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002239 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.